STOCK TITAN

Fusion Pharmaceuticals Inc. Common Shares - FUSN STOCK NEWS

Welcome to our dedicated page for Fusion Pharmaceuticals Common Shares news (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals Common Shares stock.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) is a clinical-stage oncology company based in Hamilton, Ontario, Canada, and Boston, focusing on the development of next-generation radioconjugates (RCs) for precision cancer treatments. The company specializes in targeted alpha therapy (TAT), leveraging their unique expertise in linking alpha particle-emitting isotopes to targeting molecules to create highly effective therapeutics.

Fusion’s lead program, FPI-2265, is designed specifically for metastatic castration-resistant prostate cancer (mCRPC). This innovative treatment targets the prostate-specific membrane antigen (PSMA) and is currently undergoing a Phase 2 clinical trial. FPI-2265 aims to improve patient outcomes by delivering a potent radioactive payload directly to cancer cells, minimizing damage to healthy tissues. The recent Phase 2 TATCIST trial results, presented at the AACR Annual Meeting 2024, demonstrated promising clinical activity and safety, with meaningful improvements in secondary endpoints for mCRPC patients.

Fusion’s pipeline includes several other promising candidates, such as FPI-1434, targeting the insulin growth factor 1 receptor (IGF1R), FPI-2059, targeting the neurotensin receptor 1 (NTSR1), and FPI-2068, a bispecific IgG-based RC targeting EGFR-cMET.

The recent acquisition of Fusion by AstraZeneca marks a significant milestone. AstraZeneca will acquire all of Fusion’s outstanding shares for $21.00 per share in cash, plus a non-transferable contingent value right of $3.00 per share, subject to achieving specific regulatory milestones. This acquisition, valued at approximately $2.4 billion, underscores Fusion's pivotal role in pioneering RCs and enhancing AstraZeneca's oncology portfolio.

Fusion operates a state-of-the-art Good Manufacturing Practice (GMP) compliant facility, ensuring the production of clinical doses for its expanding pipeline. The company has strategic actinium supply agreements with Niowave, Inc., and BWXT Medical to meet the growing demand for their therapies.

With a robust pipeline, strategic partnerships, and a strong balance sheet, Fusion is well-positioned to advance their mission of transforming cancer treatment through innovative alpha-emitting radioconjugates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
Rhea-AI Summary
Fusion Pharmaceuticals provides clinical and corporate updates, including progress in their pipeline, discontinuation of a program, and financial results for Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
none
-
Rhea-AI Summary

Fusion Pharmaceuticals (NASDAQ: FUSN), a clinical-stage oncology company, has announced a presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 3:00 p.m. ET. The presentation will be delivered by John Valliant, Ph.D., the Chief Executive Officer. Investors can access a live webcast of the presentation on the Company's website, with a replay available for 90 days.

Fusion specializes in developing next-generation radiopharmaceuticals, aiming to deliver targeted cancer therapies. Their clinical pipeline includes several trials targeting various cancers, including those resistant to traditional therapies. Recent collaborations with AstraZeneca and Merck highlight Fusion's commitment to advancing cancer treatment through innovative approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
conferences
Rhea-AI Summary

Fusion Pharmaceuticals (Nasdaq: FUSN) presented preclinical data supporting its clinical-stage FPI-2059, a targeted alpha therapy (TAT) aimed at neurotensin receptor 1 (NTSR1), at the AACR Annual Meeting. The data indicated that FPI-2059 effectively inhibits tumor growth in colorectal cancer models, showing strong tumor uptake and dose-dependent efficacy. Additional research highlighted the potential of targeting tumor endothelial marker 1 (TEM-1) and epidermal growth factor receptor variant 3 (EGFRvIII) for future TAT applications. The positive results from these studies underscore the company's ongoing Phase 1 study for FPI-2059 and its commitment to developing next-generation radiopharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.92%
Tags
-
Rhea-AI Summary

Fusion Pharmaceuticals (FUSN) announced the FDA clearance of IND applications for FPI-2068 and imaging analogue FPI-2107. FPI-2068 is a bispecific targeted alpha therapy (TAT) aimed at delivering actinium-225 to tumors expressing EGFR and cMET, validated targets in cancer treatment. This IND filing marks a critical milestone in the development collaboration with AstraZeneca (AZN), indicating plans for a Phase 1 clinical study. The therapy is intended to enhance tumor specificity and patient screening using corresponding imaging isotopes, potentially increasing therapeutic response rates. The development will be shared equally between Fusion and AstraZeneca through clinical phases, with Fusion managing the initial trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) announced on April 5, 2023, that its Board of Directors granted stock option awards to purchase 258,000 shares to four employees outside of the company's 2020 Stock Option and Incentive Plan. These options, priced at $3.80 per share, align with the closing price on April 3, 2023, and will vest over four years. Fusion is a clinical-stage oncology company specializing in next-generation radiopharmaceuticals, with key clinical trials underway targeting various cancers, including metastatic castration-resistant prostate cancer. The company has collaborations with AstraZeneca and Merck for innovative therapies. This move reflects Fusion's commitment to attracting talent as it advances its clinical pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
none
Rhea-AI Summary

Fusion Pharmaceuticals (Nasdaq: FUSN) has announced the first patient dosing in a Phase 1 study for [225Ac]-FPI-2059, a targeted alpha therapy aimed at treating solid tumors with neurotensin receptor 1 (NTSR1). The therapy targets tumors overexpressing NTSR1, seen in various cancers. The trial aims to assess the safety, tolerability, and early efficacy of FPI-2059. This marks Fusion's fourth clinical program, showcasing their potential in the radiopharmaceutical market. With promising early data from prior studies, the company is set to advance its pipeline of innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags

FAQ

What is the current stock price of Fusion Pharmaceuticals Common Shares (FUSN)?

The current stock price of Fusion Pharmaceuticals Common Shares (FUSN) is $21.55 as of June 3, 2024.

What is the market cap of Fusion Pharmaceuticals Common Shares (FUSN)?

The market cap of Fusion Pharmaceuticals Common Shares (FUSN) is approximately 1.8B.

What does Fusion Pharmaceuticals Inc. specialize in?

Fusion Pharmaceuticals Inc. specializes in the development of next-generation radioconjugates (RCs) for precision cancer treatments, utilizing targeted alpha therapy (TAT).

What is Fusion's lead program?

Fusion's lead program is FPI-2265, a radioconjugate targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC).

What recent achievement has Fusion Pharmaceuticals accomplished?

Fusion Pharmaceuticals has recently been acquired by AstraZeneca for $21.00 per share, plus a potential additional $3.00 per share upon achieving specific regulatory milestones.

What is the significance of the acquisition by AstraZeneca?

The acquisition by AstraZeneca significantly enhances their oncology portfolio by adding Fusion's pipeline of innovative radioconjugates and expertise in targeted alpha therapies.

Which other products are in Fusion Pharmaceuticals' pipeline?

Fusion's pipeline includes FPI-1434 targeting IGF1R, FPI-2059 targeting NTSR1, and FPI-2068 targeting EGFR-cMET.

What was revealed in the Phase 2 TATCIST trial of FPI-2265?

The Phase 2 TATCIST trial demonstrated promising clinical activity and safety for FPI-2265 in mCRPC patients, showing potential as an effective treatment option.

Where is Fusion Pharmaceuticals headquartered?

Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada, with operational presence in Boston, USA.

What type of facility does Fusion operate for manufacturing?

Fusion operates a state-of-the-art Good Manufacturing Practice (GMP) compliant facility, ensuring the production of clinical doses for its pipeline of radioconjugates.

Who are Fusion's strategic supply partners?

Fusion has strategic actinium supply agreements with Niowave, Inc. and BWXT Medical to meet the growing demand for their radioconjugates.

What financial terms were involved in AstraZeneca's acquisition of Fusion?

AstraZeneca acquired Fusion for $21.00 per share in cash plus a non-transferable contingent value right of $3.00 per share upon a regulatory milestone, valuing the transaction at approximately $2.4 billion.

Fusion Pharmaceuticals Inc. Common Shares

Nasdaq:FUSN

FUSN Rankings

FUSN Stock Data

1.83B
75.27M
0.47%
86.8%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
HAMILTON